<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231219060466N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2024-01-05</date_registration>
      <primary_sponsor>Kermanshah University of Medical Sciences</primary_sponsor>
      <public_title>Investigating the effect of wild pistachio gum in the treatment of fatty liver disease</public_title>
      <acronym></acronym>
      <scientific_title>Investigating the effect of Bane (Pistacia atlantica sub. Kurdica) gum oral supplement on the improvement of oxidant/ antioxidant and inflammatory indices, and Keap1/Nrf-2/ARE signaling pathway in patients with non-alcoholic fatty liver disease: A Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>46</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/74503</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: A random sequence will be generated by using the random block method using a random block of 4 for a total of 12 blocks that will be created using the website https://www.sealedenvelope.com.The person who collects the information is unaware of the type of allocation of the samples to the study groups. The following things will be considered regarding the implementation of the random assignment process: a) One English letter will be assigned to each of the groups: A to the supplement group, B to the placebo group. b) A sequence will be created for a sample size of 46 . c) For the concealment process of random allocation, 46 non-transparent envelopes and 46 cards (the size of the total sample size) will be prepared. Inside each envelope, 4 cards will be placed in the order of the sequence in each block. Block numbers will be written on each envelope. The name of the desired group will be written on each card in sequence.
Due to the fact that people do not know about the random sequence and the considered blocks, random allocation concealment is observed and before the allocation of the individual, the allocated group will not be clear, Blinding description: Except for an individual outside the study group who will number the randomization list and drug containers sequentially, all other investigators and all patients will be blinded to study group assignment. The placebo will be identical in shape and appearance to the supplement and will be distributed in similar containers.</study_design>
      <phase>3</phase>
      <hc_freetext>Fatty liver.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in the supplement group will take every 12 hours, 2 tablespoons of oral emulsion, each spoon containing 500 mg of Pistacia atlantica Sub Kurdica gum for 2 months. This emulsion will be produced by Barij Essential Pharmaceutical Company. Intervention 2: Control group: Patients in the placebo group will take 2 tablespoons of oral emulsion every 12 hours with the same appearance and composition as the gum supplement (but without Pistacia atlantica Sub. Kurdica gum) for 2 months. This emulsion will be produced by Barij Essential Pharmaceutical Company.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All information can be shared.

When:
6 months after the results are published

To whom:
Scientific referees of reputable journals

Conditions:
Checking the accuracy of data by reviewer

Where to obtain:
Email to corresponding author: Dr Seyed Mostafa Nachvak
smnachvak@hotmail.com

How to obtain:
Email
The expected period is one month

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Roghayeh Mostafaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dolatabad</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>671987915</zip>
        <telephone>+98 83 3827 0803</telephone>
        <email>r_mostafai@yahoo.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyed Mostafa Nachvak</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>ِDolatabad</address>
        <city>Kermanshah</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6714673159</zip>
        <telephone>+98 83 3827 2001</telephone>
        <email>smnachvak@hotmail.com</email>
        <affiliation>Kermanshah University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having fatty liver grade 1 and 2 based on diagnosis by ultrasound
Age 18-60 years
Body mass index in the range of 25-35 kg/m2</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The presence of secondary causes of hepatic steatosis (such as hepatitis B and C virus, autoimmune hepatitis, hemochromatosis, celiac disease, pituitary hypofunction, hypothyroidism, Wilson's disease, abetalipoproteinemia or corticosteroid drugs)
Suffering from diseases such as Autoimmune, digestive, liver diseases (fibrosis, cirrhosis, (HCC, kidney, thyroid and cardiovascular diseases), severe respiratory disease (asthma and chronic bronchitis)
Pregnancy
Breastfeeding
Alcohol consumption, consumption of plant sterols, psyllium and oil Fish, consumption of any kind of vitamins and minerals, nutritional supplements
The existence of allergy to all kinds of Pistachio plant species</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K76.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fatty (change of) liver, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in the supplement group will take every 12 hours, 2 tablespoons of oral emulsion, each spoon containing 500 mg of Pistacia atlantica Sub Kurdica gum for 2 months. This emulsion will be produced by Barij Essential Pharmaceutical Company.</i_keyword>
      <i_keyword>Control group: Patients in the placebo group will take 2 tablespoons of oral emulsion every 12 hours with the same appearance and composition as the gum supplement (but without Pistacia atlantica Sub. Kurdica gum) for 2 months. This emulsion will be produced by Barij Essential Pharmaceutical Company.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Oxidative stress indicators (MDA, TAC, TOS). Timepoint: Before and after study. Method of measurement: Calorimetric method.</prim_outcome>
      <prim_outcome>Gene expression of antioxidant enzymes (NQO1, HMOX-1, GCLC). Timepoint: Before and after study. Method of measurement: Real- Time PCR.</prim_outcome>
      <prim_outcome>Nrf-2 gene expression. Timepoint: Before and after study. Method of measurement: Real- Time PCR.</prim_outcome>
      <prim_outcome>Serum levels of inflammatory and anti-inflammatory factors (IL-10, IL-6). Timepoint: Before and after study. Method of measurement: ELIZA method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Fasting insulin. Timepoint: Before and after study. Method of measurement: Calorimetric method.</sec_outcome>
      <sec_outcome>Fasting blood sugar. Timepoint: Before and after study. Method of measurement: Calorimetric method.</sec_outcome>
      <sec_outcome>Insulin resistance index (HOMA-IR). Timepoint: Before and after study. Method of measurement: Formula.</sec_outcome>
      <sec_outcome>Insulin sensitivity index (QUICKI). Timepoint: Before and after study. Method of measurement: Formula.</sec_outcome>
      <sec_outcome>Function of pancreatic beta cells (HOMA-β). Timepoint: Before and after study. Method of measurement: Formula.</sec_outcome>
      <sec_outcome>Liver enzymes (AST, ALT). Timepoint: Before and after study. Method of measurement: Calorimetric method.</sec_outcome>
      <sec_outcome>Lipid profile (TC, HDL-C, TG, LDL-c). Timepoint: Before and after study. Method of measurement: Enzymatic method.</sec_outcome>
      <sec_outcome>The degree of hepatic steatosis. Timepoint: Before and after study. Method of measurement: sonography.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kermanshah University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-12-18</approval_date>
        <contact_name>Ethics Committee of Kermanshah University of Medical Sciences</contact_name>
        <contact_address>Shahid Beheshti Blvd Kermanshah Kermanshah Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
